You are here
Risperidone (trade name Risperdal and generics) is a second-generation a typical antipsychotic. It is a dopamine antagonist possessing anti-serotonergic, anti-adrenergic and anti-histaminergic properties.
The drug was developed by Janssen-Cilag, subsidiary of Johnson & Johnson, from 1988 to 1992 as an improvement from the typical antipsychotic and first approved by the FDA in 1994. Risperidone became available as a generic drug in October 2008.
Prescribed in the treatment of bipolar disorder and schizophrenia in adults and adolescents, is also used to treat irritability in children ages 5-to-16 years of age on the autism spectrum.
In February 2015, the first Risperdal trial went before a Philadelphia jury, resulting in a $2.5 million damage award for a 20 year old man who suffered gynecomastia breast growth after using the medication for treatment of autism when he was 8 years old.
Evidence presented at trial suggested that Johnson & Johnson's Janssen unit knew about the Risperdal gynecomastia risk as early as 2001, yet failed to warn consumers and the medical community. Over 1000+ cases are pending litigation in Philadelphia courts.
Evidence to look for in potential cases:
- 1. Risperdal usage by a Male in adolescence during 2006 to 2010.
- 2. Hyperprolactinemia, weight gain.
- 3. Treatment or surgery for Gynecomastia.
Medical Record Review and claim validation of Risperdal case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.